The financing will support the commercial rollout of synthetic affinity reagents and team expansion.
"Securing funding for a novel reagents company in today's investment landscape demonstrates clear confidence in MIP Discovery's technology and renewed commercial strategy. Our proprietary modeling approach to developing synthetic antibody alternatives has already been successful for diagnostic applications, and we have already seen very encouraging traction for our expertise in the cell and gene therapy space."
The financing round was led by LAUNCHub Ventures and Kadmos Capital to fund the company's shift towards the diagnostics market.
"We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being."
The oversubscribed round was backed by existing and new strategic investors to fund US expansion and generative AI development.
"This successful financial raise allows us to increase the size of our in-house development team by recruiting new talent who will focus on building Proteus’s generative AI. This will further help our clients optimise their project performance. In addition, the raise will support our growth into Australia and our planned entry into the United States later in 2024."
The seed round was led by Pracuj Ventures to fund product development and expansion into Poland and Latin America.
"Pracuj Ventures reaffirmed their commitment to HR automation and tech trends. At PeopleForce, we are proud to be part of their investment portfolio and eager to advance development, delivering the best HR platform for our customers."
